Literature DB >> 23237506

Regulatory roles of the tumor necrosis factor receptor BCMA.

Christine M Coquery1, Loren D Erickson.   

Abstract

B cell maturation antigen (BCMA) is a tumor necrosis family receptor (TNFR) member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF family (BAFF) and a proliferation inducing ligand (APRIL), delivers pro-survival cell signals. Thus, BCMA is mostly known for its functional activity in mediating the survival of plasma cells that maintain long-term humoral immunity. The expression of BCMA has also been linked to a number of cancers, autoimmune disorders, and infectious diseases that suggest additional roles for BCMA activity. Despite recent advances in our understanding of the roles for the related TNFR members BAFF-R and transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), the signaling pathway used by BCMA for mediating plasma cell survival as well as its putative function in certain disease states are not well understood. By examining the expression, regulation, and signaling targets of BCMA, we may gain further insight into this receptor and how it operates within cells in both health and disease. This information is important for identifying new therapeutic targets that may be relevant in treating diseases that involve the BAFF/APRIL cytokine network.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237506      PMCID: PMC3548317          DOI: 10.1615/critrevimmunol.v32.i4.10

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  107 in total

1.  B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.

Authors:  Vassilia-Ismini Alexaki; Vassiliki Pelekanou; George Notas; Maria Venihaki; Marilena Kampa; Valérie Dessirier; Sanaa Sabour-Alaoui; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

2.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

3.  TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.

Authors:  Claudia Bossen; Teresa G Cachero; Aubry Tardivel; Karine Ingold; Laure Willen; Max Dobles; Martin L Scott; Aris Maquelin; Elodie Belnoue; Claire-Anne Siegrist; Stéphane Chevrier; Hans Acha-Orbea; Helen Leung; Fabienne Mackay; Jürg Tschopp; Pascal Schneider
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

4.  TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production.

Authors:  Liang-Guo Xu; Hong-Bing Shu
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

5.  TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.

Authors:  Julia Hauer; Stephanie Püschner; Parameswaran Ramakrishnan; Ute Simon; Martina Bongers; Christine Federle; Hartmut Engelmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-11       Impact factor: 11.205

6.  Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

Authors:  Anne J Novak; Jaime R Darce; Bonnie K Arendt; Brandon Harder; Kathy Henderson; Wayne Kindsvogel; Jane A Gross; Philip R Greipp; Diane F Jelinek
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

7.  A molecular compendium of genes expressed in multiple myeloma.

Authors:  Jaime O Claudio; Esther Masih-Khan; Hongchang Tang; Jason Gonçalves; Michael Voralia; Zhi Hua Li; Vincent Nadeem; Eva Cukerman; Ofelia Francisco-Pabalan; Choong Chin Liew; James R Woodgett; A Keith Stewart
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor.

Authors:  Sandra Gardam; Frederic Sierro; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2008-02-28       Impact factor: 31.745

9.  Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival.

Authors:  Sara Maia; Marc Pelletier; Jixin Ding; Yen-Ming Hsu; Stephen E Sallan; Sambasiva P Rao; Lee M Nadler; Angelo A Cardoso
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  31 in total

1.  BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.

Authors:  Jooeun Bae; Neha Parayath; Wenxue Ma; Mansoor Amiji; Nikhil Munshi; Kenneth C Anderson
Journal:  Leukemia       Date:  2019-08-19       Impact factor: 11.528

2.  Gene variants associated with age at menopause are also associated with polycystic ovary syndrome, gonadotrophins and ovarian volume.

Authors:  R Saxena; A C Bjonnes; N A Georgopoulos; V Koika; D Panidis; C K Welt
Journal:  Hum Reprod       Date:  2015-05-20       Impact factor: 6.918

Review 3.  New roles for the BLyS/BAFF family in antigen-experienced B cell niches.

Authors:  Radhika Goenka; Jean L Scholz; Vishal J Sindhava; Michael P Cancro
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-10       Impact factor: 7.638

Review 4.  BAFF inhibition in SLE-Is tolerance restored?

Authors:  Shaun W Jackson; Anne Davidson
Journal:  Immunol Rev       Date:  2019-09-28       Impact factor: 12.988

5.  Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Authors:  Andrea Schmidts; Maria Ormhøj; Bryan D Choi; Allison O Taylor; Amanda A Bouffard; Irene Scarfò; Rebecca C Larson; Matthew J Frigault; Kathleen Gallagher; Ana P Castano; Lauren S Riley; Maria L Cabral; Angela C Boroughs; Rubí M-H Velasco Cárdenas; Wolfgang Schamel; Jing Zhou; Sean Mackay; Yu-Tzu Tai; Kenneth C Anderson; Marcela V Maus
Journal:  Blood Adv       Date:  2019-11-12

6.  Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.

Authors:  Zhaochun Chen; Giacomo Diaz; Teresa Pollicino; Huaying Zhao; Ronald E Engle; Peter Schuck; Chen-Hsiang Shen; Fausto Zamboni; Zhifeng Long; Juraj Kabat; Davide De Battista; Kevin W Bock; Ian N Moore; Kurt Wollenberg; Cinque Soto; Sugantha Govindarajan; Peter D Kwong; David E Kleiner; Robert H Purcell; Patrizia Farci
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-12       Impact factor: 11.205

7.  Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice.

Authors:  Julie Lang; Bicheng Zhang; Margot Kelly; Jacob N Peterson; Jacob Barbee; Brian M Freed; James P Di Santo; Jennifer L Matsuda; Raul M Torres; Roberta Pelanda
Journal:  Blood Adv       Date:  2017-12-19

8.  TSPAN33 is a novel marker of activated and malignant B cells.

Authors:  Van Phi Luu; Peter Hevezi; Felipe Vences-Catalan; José Luis Maravillas-Montero; Clayton Alexander White; Paolo Casali; Luis Llorente; Juan Jakez-Ocampo; Guadalupe Lima; Natalia Vilches-Cisneros; Juan Pablo Flores-Gutiérrez; Leopoldo Santos-Argumedo; Albert Zlotnik
Journal:  Clin Immunol       Date:  2013-08-15       Impact factor: 3.969

9.  Zoom Zoom: racing CARs for multiple myeloma.

Authors:  Marcela V Maus; Carl H June
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

10.  BAFF upregulates CD28/B7 and CD40/CD154 expression and promotes mouse T and B cell interaction in vitro via BAFF receptor.

Authors:  Feng Zhang; Shan-Shan Song; Jin-Ling Shu; Ying Li; Yu-Jing Wu; Qing-Tong Wang; Jing-Yu Chen; Yan Chang; Hua-Xun Wu; Ling-Ling Zhang; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.